Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for Mereo BioPharma Group (MREO) over the last 1 years, with Dec 2024 value amounting to $1.3 million.

  • Mereo BioPharma Group's Gains from Sales and Divestitures rose 166.89% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 166.89%. This contributed to the annual value of $1.3 million for FY2024, which is 166.89% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Gains from Sales and Divestitures stood at $1.3 million for Q4 2024, which was down 0.00% from $1.3 million recorded in Q3 2024.
  • Over the past 5 years, Mereo BioPharma Group's Gains from Sales and Divestitures peaked at $1.3 million during Q3 2024, and registered a low of $142,583 during Q1 2024.
  • In the last 2 years, Mereo BioPharma Group's Gains from Sales and Divestitures had a median value of $802,890 in 2024 and averaged $824,631.
  • Data for Mereo BioPharma Group's Gains from Sales and Divestitures shows a peak YoY skyrocketed of 166.89% (in 2024) over the last 5 years.
  • Over the past 2 years, Mereo BioPharma Group's Gains from Sales and Divestitures (Quarterly) stood at $501,380 in 2023, then spiked by 166.89% to $1.3 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.3 million for Q4 2024, versus $1.3 million for Q3 2024 and $802,890 for Q2 2024.